Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 571 to 580 of 797

TitleReference numberPublishedLast updated
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanomaTA414
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastasesTA412
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitorsTA407
Pegaspargase for treating acute lymphoblastic leukaemiaTA408
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Talimogene laherparepvec for treating unresectable metastatic melanomaTA410
Bosutinib for previously treated chronic myeloid leukaemiaTA401
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402

Results per page

  1. 10
  2. 25
  3. 50
  4. All